| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 56.3 | 76.3 |
| Net income | 40.5 | -22.2 |
| EPS (diluted, $ a share) | $0.53 | $-0.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -26.3% |
|---|---|
| Operating margin | 89.1% |
10-Q filed with the SEC, NASDAQ: HCAT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Health Catalyst, Inc.: key numbers
- Share price
- $1.37Close, Nov 17
- Market cap
- $104M
- Shares outstanding
- 76.16MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Computer Programming, Data Processing, Etc.SIC 7370
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Health Catalyst, Inc.
All →Health Catalyst General Counsel Benjamin Landry Sells $141K of Stock
Benjamin Landry, General Counsel, sold 99,478 shares of Health Catalyst, Inc. at $1.39 to $1.43 a share (average $1.42) in 2 transactions, worth $141K in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 251,894 (-10.5%).
- Value
- $141K
- Shares
- 99,478
- Average price
- $1.42
- Role
- General Counsel
- Holding change
- -10.5%
- Trade date
- Nov 11, 2026 to Nov 12, 2026
Health Catalyst Financial Results
Health Catalyst reported Q3 2026 financial results, beating the high end of its revenue and Adjusted EBITDA guidance despite a 26% year-over-year revenue decline following the divestiture of its Vitalware business. The company reported GAAP net income of $40.5 million, primarily driven by a $65.9 million gain on the sale of Vitalware, and reaffirmed its full-year 2026 outlook.
- Term
- 3 months
“We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook. Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.”
Simeon Kohl, President and Chief Executive Officer
Health Catalyst CEO Simeon Kohl Buys $105K of Stock
Simeon Kohl, CEO, bought 59,000 shares of Health Catalyst, Inc. at $1.79 a share, worth $105K in total on Sep 14, 2026. Shares held after the trade: 2,856,385 (+2.1%).
- Value
- $105K
- Shares
- 59,000
- Price
- $1.79
- Role
- CEO
- Holding change
- +2.1%
- Trade date
- Sep 14, 2026
Health Catalyst Leadership Change
Health Catalyst, Inc. appointed Tami Reller to its Board of Directors, effective October 1, 2026, expanding the board from six to seven members. Ms. Reller, a former CEO of Duly Health and Care and executive at UnitedHealth Group and Microsoft, will serve as the Chair of the Audit Committee and a member of the Compensation Committee. The appointment follows the naming of Simeon Kohl as the company's new CEO and President.
- Counterparty
- Tami Reller